Berry Oncology has launched its new HIFI Pan-Cancer Screening, which can detect six high-risk cancers in one test.
Developed using the company’s HIFI technology platform, the early screening product can accurately detect six cancers that are highly prevalent in China.
Go deeper with GlobalData
They include liver, colorectal, oesophagal, pancreatic, gastric and lung cancer.
The product has demonstrated an 82% traceability accuracy, 99.09% specificity and 87.58% sensitivity.
The company stated that the self-iterative HIFI technology platform can help reduce product development and testing service costs, which in turn contributes to the effort to make early multi-cancer screening more affordable.
Berry Oncology’s new one-time precision product is claimed to be the first of its kind in the world to be developed using whole-genome sequencing (WGS) of cell-free DNA (cfDNA).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe technology has the capability to capture early cancer signals in a broader range.
This helps to reduce missed detections, which are caused by differences in individual and molecular biological characteristics across several types of tumours.
Berry Oncology CEO Zhou Jun said: “Since its establishment, Berry Oncology has been dedicated to developing technologies and delivering products for early cancer screening based on the spectrum of malignant tumours, to help more high-risk people identify hidden risks and help more patients prolong survival time and improve quality of life.
“Moving forward, Berry Oncology will continue to optimise its technology system and iterate early screening products to deliver more advanced early cancer screening solutions in accordance with the actual market demand and environment.
“In the meanwhile, we will further our partnerships with industry players, universities and research organisations to co-build an ecosystem for cancer prevention and treatment that enables innovations more accessible.”
